[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unresectable-malignant-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unresectable-malignant-neoplasm":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100383869","phase-1-chemoradiotherapy-in-unresectable-esophageal-cancer-100383869",false,"NCT04278287","Chemoradiotherapy in Unresectable Esophageal Cancer","A Phase I\u002FII Study of Chemoradiotherapy Using Albumin-Bound Paclitaxel and Cisplatin in Unresectable Esophageal Squamous Cell Carcinomas Based on Nutritional Risk Screening Score (NRS2002)","Inclusion Criteria:\n\n* 18\\~75 years\n* Pathologically or cytologically proven unresectable esophageal squamous cell carcinomas in patients staged as T3N1M0-1b and T4N0-1M0-1b(AJCC 6th TNM staging,M1b limited to clavicular or celiac lymph node metastasis)\n* Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences\n* ECOG PS score: 0\\~1\n* NRS2002 score \\\u003C3\n* Estimated survival time ≥3 months\n* Normal organ and marrow function as defined below:\n\nHemoglobin: greater than or equal to 100g\u002FL ;Leukocytes: greater than or equal to 4,000 G\u002FL; Neutrophil: greater than or equal to 2,000 G\u002FL; Platelets: greater than or equal to 100,000\u002Fmm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml\u002Fmin; AST\u002FALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit\n\n* Informed consent\n\nExclusion Criteria:\n\n* With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc\n* Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer\n* Existing active infection such as active tuberculosis and hepatitis\n* History of myocardial infarction within the past 6 months or history of ventricular arrhythmia\n* Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\n* History of allergic reactions attributed to paclitaxel, albumin or cisplatin\n* Participation in other clinical trials currently or within 4 weeks of selection\n* Pregnant or lactating females","ALL","18 Years","75 Years",{"count":20,"type":21},105,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This phase I\u002FII clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.",[28,29,30,31],"Esophageal Cancer","Chemoradiotherapy","Albumin-bound Paxlitaxel","Unresectable Malignant Neoplasm","RECRUITING","2024-12-10",{"date":35,"type":36},"2024-12-13","ACTUAL",{"date":38,"type":36},"2019-10-01",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",5]